《大行報告》麥格理升歐舒丹(00973.HK)評級至「跑贏大市」 目標價上調至21元
麥格理發表報告指,歐舒丹(00973.HK)受惠於有效的多品牌戰略,上半財年業績表現好過預期,相信隨著英國護膚品牌Elemis併入集團,有助改善經營利潤率,預測2020及2021年度可達12.4%及12.5%。該行將其評級由「中性」升至「跑贏大市」,目標價從16.5元上調至21元。
報告續指,受表現最好的法國業務所帶動,期內歐洲同店銷售表現有所改善,內地經歷首季銷售疲軟後,第二季已恢復逾一成的增長;表現最差地區為美國、日本和香港。該行表示,第三季度香港及美國的銷售繼續疲弱,歐洲則保持較好的發展趨勢,預期未來的大型假期及季節性營銷都將有助推動銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.